Transcatheter pulmonary valve replacement in native and nonconduit right ventricle outflow tracts

Abstract

Feature Editor's Introduction-Only 2 years ago, I wrote an editorial about transcatheter pulmonary valve insertion and commented that this was a, new paradigm. 1 Successful transcatheter pulmonary valve insertion had been reported in 100 patients where the previous surgically placed bioprosthetic pulmonary valve was used as a landing zone. 2 This Invited Expert Opinion provides a perspective on the following paper:

Case report: Transcatheter pulmonary valve-in-valve implantation in a deteriorated self-expandable valve caused by infective endocarditis

“…Given the relatively low risk of procedural complications, TPVI may be an optimal option in selective cases. Although TPVI has been reported to be a feasible procedure with successful implantation rate >95% ( 4 , 5 ), it remains challenging and technically demanding in some special scenario.…”

At the forefront of congenital cardiothoracic surgery: 2020-2021

“…12 The expanding indications for transcatheter pulmonary valve replacement were explored in depth by Tannous and Nugent. 13 They reviewed the currently available transcatheter pulmonary valve devices and transcatheter approaches on the horizon for patients with native or nonconduit right ventricular outflow tracts. This, of course, is a field in which progress is accelerating with ever-improving devices from collaboration with industry.…”

Commentary: What happens next?

“…Richard D. Mainwaring, MD Transcatheter pulmonary valve replacement (PVR) has become a commonly performed procedure, with approximately 1000 procedures performed in the United States each year. 1 In their article in this issue of the Journal, Tannous and Nugent provide a very nice summary of the current state of the art for transcatheter PVR. They speculate that continued advances in technology will make it even more feasible to perform transcatheter PVR in the future.…”